Filing Details

Accession Number:
0001209191-21-026742
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-14 20:00:13
Reporting Period:
2021-04-12
Accepted Time:
2021-04-14 20:00:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1564824 Allakos Inc. ALLK Pharmaceutical Preparations (2834) 454798831
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1637219 Adam Tomasi 975 Island Drive, Suite 201
Redwood City CA 94065
President, Coo And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-04-14 20,000 $107.77 153,126 No 4 S Direct
Common Stock Acquisiton 2021-04-14 20,000 $0.69 173,126 No 4 M Direct
Common Stock Disposition 2021-04-13 20,000 $103.08 153,126 No 4 S Direct
Common Stock Acquisiton 2021-04-13 20,000 $0.69 173,126 No 4 M Direct
Common Stock Disposition 2021-04-12 20,000 $104.40 153,126 No 4 S Direct
Common Stock Acquisiton 2021-04-12 20,000 $0.69 173,126 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to buy) Disposition 2021-04-14 20,000 $0.00 20,000 $0.69
Common Stock Stock Option (Right to buy) Disposition 2021-04-13 20,000 $0.00 20,000 $0.69
Common Stock Stock Option (Right to buy) Disposition 2021-04-12 20,000 $0.00 20,000 $0.69
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
586,400 2027-05-17 No 4 M Direct
606,400 2027-05-17 No 4 M Direct
626,400 2027-05-17 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,953 Indirect See footnote
Footnotes
  1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. This transaction was executed in multiple trades at prices ranging from $103.62 to $108.86 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
  2. Includes shares of common stock purchased under the Company's 2018 Employee Stock Purchase Plan.
  3. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. This transaction was executed in multiple trades at prices ranging from $101.43 to $105.55 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
  4. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. This transaction was executed in multiple trades at prices ranging from $102.19 to $106.17 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
  5. Includes 3,953 shares received as a pro-rata in-kind distribution of Common Stock of the Issuer by Alta Partners Management VIII, LLC (APM VIII), without consideration, to the reporting person as a non-managing member of APM VIII.
  6. The shares are held by Mr. Tomasi and Carrie Tomasi, as Trustees of the Tomasi Living Trust dated July 14, 2017.
  7. On May 17, 2017, the Reporting Person was granted an option to purchase 706,400 ordinary shares pursuant to the Company's 2012 Equity Incentive Plan. The option vests as to one-fourth of the shares on May 17, 2018, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.